Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 9.9% – Here’s Why

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares fell 9.9% on Thursday . The stock traded as low as $12.86 and last traded at $12.8130. 778,966 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,898,585 shares. The stock had previously closed at $14.22.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ADPT shares. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Stock Down 14.6%

The company’s 50-day moving average is $16.68 and its two-hundred day moving average is $15.87. The company has a market capitalization of $1.87 billion, a P/E ratio of -30.52 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.23) EPS. On average, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In other news, COO Julie Rubinstein sold 19,460 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80. Following the transaction, the chief operating officer directly owned 643,471 shares in the company, valued at approximately $9,446,154.28. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Chad M. Robins sold 53,083 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $15.52, for a total value of $823,848.16. Following the transaction, the chief executive officer directly owned 1,934,247 shares in the company, valued at approximately $30,019,513.44. This represents a 2.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 1,209,806 shares of company stock worth $19,656,239. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ADPT. AQR Capital Management LLC raised its position in Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of Adaptive Biotechnologies in the first quarter worth about $93,000. Envestnet Asset Management Inc. bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $467,000. Finally, Savant Capital LLC lifted its stake in shares of Adaptive Biotechnologies by 15.4% in the 2nd quarter. Savant Capital LLC now owns 39,665 shares of the company’s stock valued at $462,000 after acquiring an additional 5,305 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.